iTeos Therapeutics Inc ITOS shares are trading higher by 36.7% at $27.38 Monday afternoon after the company and GlaxoSmithKline announced an agreement to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody.
See Also: iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
